Lonza expands Solid Form Services with their Facility in Oregon
Lonza enhances their capabilities in small molecules by expanding their facility in Bend, Oregon, USA to assist small biotechnology and pharmaceutical companies in this area.
Lonza Small Molecules have been working to establish themselves fully in the small molecules market and have now announced the completion of their expanded Solid Form Services (SFS) offering for small molecule drugs.
The specialised facility, situated in Bend, OR (USA), reached operational level at the end of 2022. This boosted Lonza’s capabilities and increases their ability to meet certain accelerated timelines necessary for the manufacture of more complex molecules.
The facility now includes refurbished laboratory space dedicated to the support of small and midsize biotech and pharma companies who are working on developing key early-stage compounds. The facility can be used for solid form screening, characterisation of small APIs, and selection and early crystallisation process development. These screening and selection processes are key for all stages of development of compounds, helping to reduce any associated risks and also helping with intellectual property claims.
Michael Morgen, Head of Advanced Drug Delivery Technologies, Small Molecules, Lonza commented: “With the completion of this expansion at our Bend site, we have successfully established a collaborative, deeply science-based Solid Form Services offering to support customers in advancing compounds to the clinic and beyond. This offering is fully integrated with our upstream drug substance, and downstream drug formulation and drug product development capabilities. We are seeing strong interest from our growing customer portfolio, with many customers bringing multiple compounds and projects to the facility.”
The growth at the new facility includes being stocked with the latest equipment necessary to assist these biotechs and small pharma companies. The lab includes powder and fume hoods, and small scale crystallisation systems. Imaging techniques including spectroscopic, thermal, and a suite of others are all catered for.
The SFS include the specialist team working at the facility, who have a wealth of experience in mapping solid form landscapes and in the selection and development of salts and polymorphs, which complements nicely the expertise in upstream drug substance and downstream drug product areas that the facility brings. Companies supported by the facility and the adjacent services can make full use of the integrated capabilities across the Lonza portfolio, from drug substance in Nansha, China to micronisation in Monteggio, Italy.
Related News
-
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News Roche breaks into the obesity drug market with the acquisition of Carmot Therapeutics
In a bid to diversify their therapeutic offerings, Roche takes over Carmot Therapeutics in $2.7 billion deal, with one obesity drug spearheading the venture into the field as they prep for a Phase II in-human trial. -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News Women in Pharma: Delivering solutions for gender diversity
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona Speaker Interview – What the US FDA’s Quality Management Maturity Means for the Pharma Industry
At CPHI Barcelona (24–26 October, 2023), we spoke to Sireesha Yadlapalli, CEO of Pharmatech Associates, who gave a presentation on the implications of the US FDA’s Quality Management Maturity (QMM) Initiative, and spoke on the panel of the ... -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Wegovy and weight-loss drugs driving demand for manufacturers that can fill syringes
Injectable weight-loss treatments are prompting contract manufacturers to invest and include fill-finish services into their service portfolios, in a bid to attract pharmaceutical giants developing drugs similar to Novo Nordisk's Wegovy.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance